Citigroup Initiates Coverage on Hengrui Pharma with Buy Rating, Sets HK$134 Price Target

Stock News16:05

Citigroup has issued a research report assigning a Buy rating to HENGRUI PHARMA H-shares with a target price of HK$134. The report highlighted that Hengrui's innovative drug sales reached RMB 4.5 billion in the first quarter of 2026, representing a 26% year-on-year increase. These sales accounted for 62% of total product sales, up from 54% in the same period last year. Management reaffirmed its target of achieving over 30% annual growth in innovative drug sales for 2026, noting that accelerated hospital access in March has laid a foundation for full-year sales growth. The company recognized RMB 787 million in business development revenue from its collaboration with GSK in the first quarter of 2026, with full-year projections around RMB 250 million. Collaborative product development is progressing smoothly, with the global Phase III trial for Ribupatide (GLP-1/GIP) initiated in December 2025, and the global Phase III trial for HRS-1893 (Myosin) scheduled to commence in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment